March 6th 2024
Findings from an open-label trial support the FDA approval of inotuzumab ozogamicin as a treatment for pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
February 12th 2024
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Markers Could Improve Treatment Stratification for Pediatric Medulloblastoma
October 3rd 2016The use of an intensified treatment regimen to treat metastatic medulloblastoma in children and adolescents conferred an overall favorable survival, according to the results of a recent study. However, patients within varying subgroups and with certain biologic parameters did not have uniform outcomes.
Early Relapse More Likely in Children With ALL From High Poverty Areas
February 24th 2016Although a child’s socioeconomic status did not seem to significantly affect 5-year overall survival ALL, those children who were from high-poverty areas experienced early relapse compared with children who were from low-poverty areas.
Obesity and Metabolic Disease After Childhood Cancer
In this review, childhood cancer survivor populations at risk for metabolic late effects, as well as mechanisms and ongoing intervention studies, will be detailed.
Role of Fukushima Radiation Unclear in Pediatric Thyroid Cancers?
October 21st 2015It is too soon to determine the influence of radiation exposure on thyroid cancer risk among children and adolescents exposed to the 2011 Fukushima Daiichi nuclear power plant disaster in Japan, according to the lead author of findings presented at the 85th Annual Meeting of the ATA.